Let’s explore the world of antibody drug conjugates (ADCs) and their potential for improving human health. Our two guests—Principal Investigator Sasha Ebrahimi from GSK and oncologist Dr. Paolo Tarantino—discuss the development and advantages of ADCs, and how they can be used to personalize treatments for cancer and other illnesses. Sasha explains how ADCs combine the targeting capabilities of antibodies with the cytotoxic effects of drugs, while Dr. Tarantino delves into his research with breast cancer and immunotherapies. Learn more about the possibilities of ADCs in this insightful episode of Discovery Matters.
Keywords: antibody drug conjugates, adc, chemotherapy, antibodies, cancer, oncology, patient, breast cancer.

Ver todos los episodios